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Purpose: to test the hypothesis that there is a negative association between serum levels of lipoprotein(a) (Lp(a)) and elastin-
derived peptides (EDP) as well as matrix metalloproteinase (MMP)-9 activation in the aneurysm wall in patients with
asymptomatic abdominal aortic aneurysms (AAA).
Material and Methods: from 30 patients operated for asymptomatic AAAs, preoperative serum samples and AAA biopsies
were collected. Lp(a) (mg/L) and EDP (ng/ml) in serum were measured by enzyme linked immunosorbent assays. MMP-9
activity (arbitrary units) in the AAA wall was measured by gelatin zymography and the ratio: active MMP-9/total MMP-9
were calculated.
Results: there was a significant negative correlation (Spearman’s rho) between serum levels of Lp(a) and EDP (r ¼ 20.707,
p , 0.001), as well as the share of activated MMP-9 (r ¼ 20.461, p ¼ 0.01) in the AAA wall.
Conclusion: this preliminary study indicate that Lp(a) inhibit elastolysis in asymptomatic AAA.
Key Words: Abdominal aortic aneurysms; Lipoprotein(a); Elastin; Elastin-derived peptides; Elastolysis; Matrix
metalloproteinases.
Introduction
Lipoprotein(a) (Lp(a)) was discovered by Berg in
1963.1 Several studies have shown that Lp(a) plays a
significant role in atherogenesis and has been estab-
lished as an independent risk marker of atherosclero-
sis.2 Serum levels of Lp(a) have been shown to be
elevated in patients with abdominal aortic aneurysms
(AAA)3,4 independently of cardiovascular risk factors
and the extent of atherosclerosis.5 Lp(a) is entrapped
in the aneurysm wall and thrombus.4
An interesting aspect of Lp(a) is that the lipid and
protein composition is similar to that of LDL(6) with
the exception of an extra glycoprotein, apolipopro-
tein(a) (apo(a)) linked to apoB-100(7) by a disulfide
linkage. Apo(a) has been identified as a member of the
plasminogen gene family.8 – 10 In apo(a) there are
kringle modules structurally related to those of
plasminogen, the precursor of plasmin in the fibrino-
lytic system, endowing Lp(a) with the ability to
compete with plasminogen for binding to fibrin11,12
and cell membranes.13,14 Thereby plasmin generation
is inhibited.15 Since apo(a) cannot be transformed
into a plasmin-like enzyme by tissue-plasminogen
activator (t-PA)16,17 and apo(a) has no protease activity
towards substrates for plasmin18 plasmin-like activity
is impaired. Additionally, Lp(a) enhance the expres-
sion of plasminogen activator inhibitor-1 (PAI-1)19 and
inhibit endothelial cell synthesis of t-PA20 thereby
further reducing plasmin generation.
In AAA, the fibrinolytic (plasminogen/plasmin)
and matrix metalloproteinase (MMP) systems are
working in concert, degrading components of the
extracellular matrix (ECM) of the aortic wall. Whereas
MMPs directly degrade several ECM components,
such as elastin and collagen, the plasminogen/plas-
min system have a limited direct proteolytic activity
against ECM components and acts mainly indirect by
activating pro-MMPs (pro-MMP-1 pro-MMP-3, pro-
MMP-9, pro-MMP-10, pro-MMP-13)21 (Fig. 1).
MMP-9 play a significant role in AAA formation
and progression towards rupture.22 – 24 MMP-9 has
significant elastolytic as well as collagenolytic capacity
and plasmin directly activates proMMP-9.25 Impaired
generation of plasmin by Lp(a) may therefore decrease
elastolysis and the generation of elastin-derived
peptides (EDP) through reduced activation of MMP-9.
The aim of this study was to test the hypothesis that
there is a negative association between serum levels of
Lp(a) and elastolysis in patients with asymptomatic
AAA.
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Materials and Methods
Thirty consecutive patients having surgical repair of
an asymptomatic infrarenal AAA were included in the
study. None of the patients were on anti-lipid therapy.
Patient demographics are shown in Table 1. AAA
diameter was measured by CT-scan. Routine measure-
ments of serum creatinin (mmol/L) were made.
Serum samples were collected by antecubital
venous puncture the day before surgery. Per-opera-
tively a full thickness specimen was collected from the
anterior aneurysm wall. The tissues were rinsed for
blood, thrombus and connective tissue and stored in
2708C until analysis.
The study was approved by the local scientific
ethics committee. All patients gave informed consent.
Measurements
Lp(a): the apo(a) content was measured in serum by
a Tint ELISA (Biopool AB, Umea˚ Sweden) utilizing
affinity purified polyclonal goat antibodies raised
against apo(a). The results were given as total Lp(a)
in mg/L. The detection limit was 0 mg/L and the
interassay CV were 7.7% at 100 mg/L and 2.7% at
400 mg/L. The corresponding intraassay CV were
6.6 and 2.3% according to the manufacturer. The
analyses were performed at the Department of
Clinical Chemistry, Umea˚ University.
EDP: serum levels of EDP were measured by a
competitive ELISA as described elsewhere.26
MMP activity: gelatine zymography was used to
estimate MMP-9 activity in the AAA wall as pre-
viously described.23 The gelatinolytic activities of pro-
MMP-9 (92 kDa) and active MMP-9 (84 kDa) were
quantified by densitometry using 2020 Ultrascan Laser
Densitometer (LKB, Sweden). The intra-assay CV of
gelatine zymography was 10.9% and the inter-assay
CV 10.8%. For each of the patients and MMPs the ratio
between active MMP and total MMP activity was
calculated.
Fig. 1. Schematic presentation of interactions between the plasminogen/plasmin and the MMP systems. The homology
between apo(a) and plasminogen implies that Lp(a) competes with plasminogen for binding on fibrin and cell receptors,
leading to reduced plasmin generation and MMP-9 activation. Additionally, Lp(a) enhance the expression of PAI-1 and
inhibit endothelial cell synthesis of t-PA thereby further reducing plasmin generation and MMP-9 activation. As MMP-9 is a
potent elastase, elastolysis is hypothetically inhibitet.
Table 1. Demographics of the patient group.
n ¼ 30
Age (years) (median, range) 65 (52–84)
Gender (F/M) 5/25
AAA diameter (cm) (median, range) 6 (5–10)
Diabetes mellitus (n (%)) 3 (10)
Serum creatinine (mmol/L) (median, range) 92 (65–344)
Arterial hypertension (n (%)) 15 (50)
Smoking (n (%)) 11 (37)
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Statistics
The statistical calculations were performed using SPSS
11.0. Spearman’s rank correlation analysis was used
for univariate analyses. After log transformation of
Lp(a) a multiple linear regression analysis using Lp(a)
as the dependent variable was performed to adjust for
potential confounding factors. However, Lp(a) failed
even after transformation to be reasonably normally
distributed.
Statistical significance was set at 95% ðp , 0:05Þ:
Assuming a correlation ðr ¼ 0:5Þ exist between the
variables serum Lp(a) and serum EDP or active MMP-
9/total MMP-9, a number of 30 patients would allow a
86% chance of detecting a correlation this large at the
chosen level of statistical significance (Sample Power
1.0).
Results
The distribution of serum Lp(a) in the AAA patients
was skewed (Fig. 2).
Serum Lp(a) was negatively correlated (Spearman’s
rho) to serum EDP (r ¼ 20:707; p , 0:001) (Fig. 3) and
the share of active MMP-9 (r ¼ 20:461; p ¼ 0:01) in the
AAA wall (Fig. 4).
Both serum EDP and the share of activated MMP-9
in the AAA wall were still significantly correlated to
serum Lp(a) after adjustment for age, gender, diabetes
mellitus, serum creatinin, AAA diameter, hyperten-
sion and smoking. Among these variables serum
creatinin (mmol/L) was positively correlated with
Lp(a) (r ¼ 0:373; p , 0:05).
Discussion
We found a significant inverse association between
serum levels of Lp(a) and EDP as well as the share of
activated MMP-9 in the AAA wall of patients with
asymptomatic AAA. As serum EDP seems to reflect
elastin turnover in the presence of a pathological
process,27,28 our results therefore indicate that Lp(a)
may have a significant influence on the elastolytic
process in AAA disease, through inhibition of plasmin
generation and decreased activation of MMP-9 (Fig. 1).
It is recognized that MMP-9 plays a critical role in
aneurysm formation22 and progression towards rup-
ture.23,24 In a guinea pig-to-rat aortic xenograft model,
seeded with syngeneic rat smooth muscle cells retro-
virally transduced with rat PAI-1 cDNA, over
expression of PAI-1 resulted in inhibition of t-PA and
lower levels of MMP-9 activity as well as prevention of
aneurysm formation and arterial rupture.29 Accord-
ingly, the enhancement of PAI-1 expression19 and
inhibition of endothelial cell t-PA synthesis20 executed
by Lp(a) may thereby theoretically and to some extent
inhibit AAA formation and progression towards
rupture. It has previously been reported that elevated
plasma levels of Lp(a) were not a risk marker for AAA
rupture.30 However, our results may indicate that low
levels of Lp(a) may be a possible marker of AAA
progression towards rupture.
The elastolytic activity of MMP-9 in the AAA wall is
dependent of the total amount of activated MMP-9
present. The ratio active MMP-9/total MMP-9 calcu-
lated in this study reflects only the magnitude of
proMMP-9 activation in which plasmin is participat-
ing. The physiologic role of Lp(a) has not been entirely
determined yet. Elevated levels of Lp(a) is believed
cause endothelial damage and thus may increase the
susceptibility for intimal injury and initiation of
aneurysm formation. It has also been suggested to
play a role in thrombus formation and reinforcement
of the aortic wall in AAA disease. AAA concentrations
of Lp(a) is correlated to Lp(a) plasma levels and is 5
times higher in the thrombus than in the aneurysm
wall.4 Lp(a) is thus present in AAA and may influence
proteolysis and thrombus formation. However, pre-
vious findings that rapid increase of thrombus area is a
predictor of AAA rupture31 do not correspond with
our results. Increased concentrations of Lp(a) may
promote further thrombus formation because of its
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Fig. 2. Distribution of Lp(a) in the patient group.
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thrombogenic effect, whereas proteolysis may be
inhibited, theoretically decreasing progression
towards rupture.
Hypertriglyceridemia has been shown to be associ-
ated with low Lp(a) levels32 and AAA rupture.30 These
observations are in accordance with our results as
Lp(a) may be a common link, between triglycerides
and ECM degradation in the aortic wall.
Lp(a) has been found not to be correlated to AAA
expansion rate.33 Increased MMP-2 but not MMP-9
levels are associated with large size AAA.24 As
proMMP-2 activation is a two-step process,25 resulting
in an intermediate 64 kDa form generated by MMP-14
and a mature 62 kDa form generated by plasmin, the
indirect influence of Lp(a) on MMP-2 activation and
possibly AAA expansion is dependent of step one. We
were not able to identify the intermediate (64 kDa)
MMP-2 on the zymograms and therefore the indirect
influence of Lp(a) on proMMP-2 activation could not
be evaluated.
Among Caucasians the distribution of Lp(a) levels
are highly skewed,34 a distribution also found in the
present study (Fig. 2). We found no correlation
between age and Lp(a) levels, an association otherwise
earlier described.35 One of the main sites of catabolism
of Lp(a) is the kidney. Renal dysfunction may lead to
accumulation of Lp(a) and to increased serum levels.36
We found an sleigh positive correlation between
serum creatinin and Lp(a) in our patients. It may be
speculated that renal dysfunction theoretically may
exert some inhibitory influence on AAA disease.
Although this study is small and preliminary it
generates some interesting speculations and ques-
tions. What impact may antilipid drug therapy have
on aneurysm formation and progression? It may be
speculated whether efforts to decrease atherogenesis
and the risk of thrombogenic and embolic compli-
cations by lowering LDL, including Lp(a), may imply
that increased risk of AAA formation and compli-
cations come without fail. Recently, it has been shown
that antilipid treatment with niacin or statins effec-
tively lowers Lp(a) levels.37 – 39 Additionally there are
evidence that aspirin also decrease serum Lp(a)
concentrations.40 The observations in recent years
that death from coronary heart disease and cerebro-
vascular disease is decreasing41 whereas death from
AAA disease is not42 may theoretically and to some
extent be explained by the use of aspirin and antilipid
drug therapy.
The increased presence of the obligate intracellular
bacterium Chlamydia pneumoniae in AAA tissue com-
pared to non-aneurysmal aortic tissue43 and increased
Lp(a) levels in AAA patients3 – 5 may start speculations
on a possible influence of circulating immune com-
plexes containing Lp(a) and C. pneumoniae specific IgG
antibodies on AAA formation and progression. A
hypothesis linking immunological mechanisms, high
Lp(a) levels, C. pneumoniae and atherosclerosis was
proposed by Dahle`n.44 As it has been proposed that
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Fig. 3. Association between serum levels of Lp(a) and EDP
(Spearmen’s rho).
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Fig. 4. Association between serum levels of Lp(a) and the
share of activated MMP-9 to total MMP-9 in the AAA wall
(Spearmen’s rho).
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aneurysmal disease partially represents an immune-
mediated disease,45 studies on these circulating
immune complexes could be interesting.
In conclusion, this small and preliminary study
suggest an inverse association between serum Lp(a)
and elastolysis in patients with asymptomatic AAA.
Further studies on the influence of Lp(a) on AAA
disease is warranted.
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